[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 19, 2002

Plasma Lysophosphatidic Acid Concentration and Ovarian Cancer

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(23):3081-3082. doi:10.1001/jama.287.23.3077

To the Editor: Xu et al1 previously reported that lysophosphatidic acid (LPA) levels are increased in the plasma of patients with ovarian cancer, and they proposed that LPA may be a useful early marker of ovarian cancer. Other studies have also reported that LPA levels are increased in malignant effusions in patients with cancer,2,3 particularly of the ovaries.4 To assess the utility of LPA as a marker of ovarian cancer, we measured the amount of LPA in plasma from patients with ovarian cancer and from healthy control subjects, as well as LPA levels in fluid from malignant effusions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×